ENDEAVOR: A phase 3 study of carfilzomib and dexamethasone versus bortezomib and dexamethasone in patients with relapsed multiple myeloma | Dr Jesús San Miguel at EHA 2015

ENDEAVOR: A phase 3 study of carfilzomib and dexamethasone versus bortezomib and dexamethasone in patients with relapsed multiple myeloma | Dr Jesús San Miguel at EHA 2015

EMJ

4 years
1,092 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
At the 20th Congress of the European Hematology Association (EHA), Jesús F. San Miguel, MD, of the Clínica Universidad de Navarra, Navarra, Spain, discusses the results of the multicentre, open-label, randomised phase 3 ENDEAVOR study of carfilzomib and dexamethasone versus bortezomib and dexamethasone in patients with relapsed multiple myeloma.



European Medical Journal

Website: http://emjreviews.com/
Twitter: https://twitter.com/EMJReviews
Facebook: https://www.facebook.com/emjreviews
Up Next Autoplay